Automation Advantage NeuMoDx's fully automated sample-to-result platforms (NeuMoDx 288 and 96) integrate robotics, microfluidics, and proprietary NeuDry reagent technology to deliver high throughput and reduced waste. This scalability makes it attractive to central laboratories and hospital networks seeking ROI through faster results, lower labor costs, and easier expansion of multi-assay menus on a single system.

GBS Opportunity FDA clearance for the GBS assay opens opportunities in obstetrics and perinatal testing. Pair this with cross-sell potential for additional infectious disease panels and LDTs on the NeuMoDx platform to grow revenue with OB/GYN labs, labor and delivery units, and neonatal care centers in the U.S. and CE markets.

EU Growth CE-IVD approvals in CMV, EBV, HBV, and HCV plus EU Vantage test indicate a clear path for European expansion. Focus sales efforts on EU distributors and hospital networks, while leveraging regulatory approvals to accelerate cross-market selling into existing U.S. accounts that are expanding internationally.

Respiratory Leadership The Flu A-B/RSV/SARS-CoV-2 Vantage test demonstrates NeuMoDx’s capability for multi-analyte respiratory panels and seasonal demand. Target clinics, urgent care centers, and reference labs requiring bundled respiratory diagnostics and rapid throughput, and pursue bundled or contracted supply deals for respiratory testing programs.

Partnerships and LDTs Past partnerships and acquisition activity show openness to co-development and distribution deals. Leverage broad general reagents and LDT compatibility to propose collaborative panels (HPV, STI, obstetric and neonatal tests) with labs and distributors, accelerating market access and menu expansion.